Results 241 to 250 of about 24,516 (282)

Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis. [PDF]

J Health Econ Outcomes Res
Tantravahi SK, Latremouille-Viau D, Desai R, Lee S, Paulose J, Geevarghese A, Guérin A, Seshasayee S, Chanpura M, Yen G.   +9 more
europepmc   +1 more source

Early Identification and Eculizumab Treatment of Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: A Case Report. [PDF]

Cureus
Wang J, Zhou Y, Xu Q.
europepmc   +1 more source

The cost-effectiveness of replacing lifelong therapy of eculizumab with a strategy of disease monitoring for eligible atypical haemolytic uraemic syndrome (aHUS) patients: an economic evaluation of the SETS aHUS trial

Orozco-Leal G, Vale. Sancha H. L., Oluboyede Y, Brocklebank V, Bryant A, Chadwick T, Dunn S, Johnson S, Kavanagh D, Dan Kennedy, Lecouturier J, Weetman C, Wong E, Woodward Susan L., Sheerin NS   +14 more
openalex  

Some of the next articles are maybe not open access.

Related searches:

Eculizumab☆

Reactions Weekly, 2010
In deep review on eculizumab pharmacology and ...
CATALDI, MAURO, A. Cavaccini
openaire   +3 more sources

Eculizumab

Reactions Weekly, 2023
  +8 more sources

Eculizumab

American Journal of Health-System Pharmacy, 2008
The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of eculizumab are reviewed.Eculizumab, a recombinant, humanized, monoclonal, immunoglobulin G antibody produced from murine myeloma cells, is the first agent to be approved for labeling by the Food and Drug ...
openaire   +2 more sources

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria

American journal of hematology/oncology
Crovalimab, a novel C5 inhibitor, allows for low‐volume, every‐4‐ week, subcutaneous self‐administration. COMMODORE 1 (NCT04432584) is a phase 3, global, randomized trial evaluating crovalimab versus eculizumab in C5 inhibitor‐experienced patients with ...
Phillip Scheinberg, D. Clé, Jin Seok Kim, E. Nur, M. Yenerel, W. Barcellini, Debora Bonito, V. Giai, Marek Hus, YooJin Lee, Cristina Barrenetxea Lekue, J. Panse, Yasutaka Ueda, Simon Buatois, Brittany Gentile, A. Kiialainen, Himika Patel, S. Sreckovic, Marianne Uguen, John Edwards, Zsolt Nagy, A. Kulasekararaj   +21 more
semanticscholar   +1 more source